Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary

4Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thrombocytopenia represents one of the most prevalent hematologic complications observed in patients infected with the human immunodeficiency virus (HIV). In this study, we sought to analyze the clinical characteristics and treatment outcomes of patients with coexisting HIV and thrombocytopenia. Specifically, we retrospectively examined the medical records of 45 patients diagnosed with HIV/AIDS and thrombocytopenia at the Yunnan Infectious Diseases Specialist Hospital between January 2010 and December 2020, all of whom received highly active antiretroviral therapy (HAART) with/without glucocorticoids. The median follow-up period was 79 days, ranging between 14 and 368 days, the total platelet count was higher after receiving treatment than before (Z = −5.662, P

Cite

CITATION STYLE

APA

Tan, Y. X., Che, L., Bi, H., Fan, S. S., Zhou, Z. P., & Min, H. Y. (2023). Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary. Platelets, 34(1). https://doi.org/10.1080/09537104.2023.2200836

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free